|
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
|
Feb 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
|
Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
|
Sep 2013
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Polymorphisms of Interlukin-1β rs16944 confer susceptibility to myelodysplastic syndromes
|
Nov 2016
|
Life Sci.
|
myelodysplastic syndromes (MDS)
|
|
Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.
|
May 2017
|
Bone Marrow Transplant
|
aplastic anemia
|
|
Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis
|
Sep 2016
|
Hematol Rep
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat
|
Feb 2021
|
Journal for immunotherapy of cancer
|
myelodysplastic syndromes (MDS)
|
|
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag
|
Apr 2021
|
Haematologica
|
aplastic anemia
|
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
|
Oct 2023
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia
|
Aug 2017
|
Ann Hematol
|
aplastic anemia
|
